DDInter1467 DDInter1376
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pimavanserin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Pimavanserin may lead to a major life threatening interaction when taken with Toremifene
Pimavanserin may lead to a major life threatening interaction when taken with Vemurafenib